SBRT May Beat Brachytherapy in Prostate Cancer

Published Date: 27 Feb 2026

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

Read Full News

Latest News

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Todays Updates

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Latest News

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

A phase 2 study investigates the combination of cladribine plus low-dose cytarabine and venetoclax alternating with azacitidine plus venetoclax for newly diagnosed acute myeloid leukemia.

News All Time

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

There’s now a hint that GLP-1 receptor agonists might prevent hysterectomies in endometrial intraepithelial neoplasia/early-stage endometrial cancer, but prospective trials are needed to confirm it.

Infection Burden High With Myeloma T-Cell Therapies

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Radioligand Therapy Set to Transform Oncology Care

Nearly 400 trials and Belgium’s isotope hub signal rapid clinical diversification for radioligand therapy — but policy, funding, and system readiness must follow.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.